Featured Publications
Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation.
Ioannou G, Berry K, Rajeevan N, Li Y, Mutalik P, Yan L, Bui D, Cunningham F, Hynes D, Rowneki M, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Osborne T, Viglianti E, Aslan M, Huang G, Bajema K. Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation. Annals Of Internal Medicine 2023, 176: 1486-1497. PMID: 37903369, PMCID: PMC10620954, DOI: 10.7326/m23-1394.Peer-Reviewed Original ResearchConceptsAcute COVID-19Veterans Health AdministrationUntreated comparatorsThromboembolic eventsCOVID-19Severe COVID-19Target trial emulationSARS-CoV-2Post COVID-19 conditionIndex dateVenous thromboembolismBaseline characteristicsCumulative incidencePulmonary embolismAcute infectionMedian ageOral antiviralsTrial emulationVHA careOutpatient treatmentInternational ClassificationHealth AdministrationU.S. veteransVeterans AffairsOrgan systemsEffectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes
Bajema K, Berry K, Streja E, Rajeevan N, Li Y, Mutalik P, Yan L, Cunningham F, Hynes D, Rowneki M, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Osborne T, Viglianti E, Aslan M, Huang G, Ioannou G. Effectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes. Annals Of Internal Medicine 2023, 176: m22-3565. PMID: 37276589, PMCID: PMC10243488, DOI: 10.7326/m22-3565.Peer-Reviewed Original ResearchConceptsVeterans Health AdministrationCOVID-19 symptom onsetCOVID-19-related outcomesSevere COVID-19Six-month outcomesCOVID-19 vaccinationCOVID-19 treatmentCOVID-19SARS-CoV-2Percent of participantsUntreated control participantsCause mortalitySymptom onsetMedian ageOral antiviralsVHA careOutpatient treatmentHospitalizationHealth AdministrationDay 31U.S. veteransVariant transmissionMost veteransVeterans AffairsOne monthEarly Adoption of Anti–SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022
Bajema K, Wang X, Hynes D, Rowneki M, Hickok A, Cunningham F, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Viglianti E, Streja E, Yan L, Aslan M, Huang G, Ioannou G. Early Adoption of Anti–SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022. JAMA Network Open 2022, 5: e2241434. PMID: 36367727, PMCID: PMC9652752, DOI: 10.1001/jamanetworkopen.2022.41434.Peer-Reviewed Original ResearchConceptsCOVID-19 pharmacotherapySevere COVID-19SARS-CoV-2Health care systemCohort studyRisk factorsCare systemMedical conditionsCOVID-19Positive SARS-CoV-2 testVeterans Affairs Health Care SystemCOVID-19-related hospitalizationCOVID-19-related symptomsLarge integrated health care systemSARS-CoV-2 testVA health care systemIntegrated health care systemNon-Hispanic veteransModerate COVID-19Odds of receiptMultivariable logistic regressionCOVID-19 vaccinationMedical comorbiditiesMedian ageAnti-SARS
2024
Platelet rich plasma alleviates endometritis induced by lipopolysaccharide in mice via inhibiting TLR4/NF‐κB signaling pathway
Liu X, Wang Y, Wen X, Hao C, Ma J, Yan L. Platelet rich plasma alleviates endometritis induced by lipopolysaccharide in mice via inhibiting TLR4/NF‐κB signaling pathway. American Journal Of Reproductive Immunology 2024, 91: e13833. PMID: 38467595, DOI: 10.1111/aji.13833.Peer-Reviewed Original ResearchConceptsPlatelet-rich plasmaPlatelet-rich plasma treatmentTLR4/NF-kB pathwayUterine tissuePlatelet-rich-plasma intrauterine infusionMouse model of endometritisRich plasmaEffect of platelet-rich plasmaInfiltration of inflammatory cellsProduction of proinflammatory cytokinesNitric oxideExpression of TNF-aHematoxylin-eosin stainingProtective effect of platelet-rich plasmaSignaling pathwayAnti-inflammatory effectsIntrauterine perfusionSuppressed LPS-induced activationTLR4/NF-kB signaling pathwayProinflammatory chemokinesReal-time PCRConcentrations of nitric oxideInflammatory cellsProinflammatory cytokinesOccurrence of infertility
2023
6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio) Hexanol Inhibits Proliferation and Induces Apoptosis of Endometriosis by Regulating Glutathione S-Transferase Mu Class 4
Liu W, Cheng L, Du Y, Liu X, Ma J, Yan L. 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio) Hexanol Inhibits Proliferation and Induces Apoptosis of Endometriosis by Regulating Glutathione S-Transferase Mu Class 4. Reproductive Sciences 2023, 30: 2945-2961. PMID: 36928896, DOI: 10.1007/s43032-023-01207-x.Peer-Reviewed Original ResearchConceptsNormal endometrial stromal cellsEndometrial stromal cellsMatrix metalloproteinase-9Cell Counting Kit-8Endometriosis patientsPrimary endometrial stromal cellsStromal cellsTreatment of endometriosisProgression of endometriosisExpression of Nrf2Kelch-like ECHCounting Kit-8Apoptotic protein BaxCell nuclear antigenOxidative stress-induced apoptosisChronic inflammationClass 4Healthy controlsInhibits cell growthPrognostic markerChronic diseasesMetalloproteinase-9SiRNA-mediated knockdownEndometriosisKeap1 expression